Search: onr:"swepub:oai:lup.lub.lu.se:95d483b6-e0e8-401a-a0d0-bf17b6061b15" > Acquired immune res...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04947naa a2200553 4500 | |
001 | oai:lup.lub.lu.se:95d483b6-e0e8-401a-a0d0-bf17b6061b15 | |
003 | SwePub | |
008 | 171010s2017 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/95d483b6-e0e8-401a-a0d0-bf17b6061b152 URI |
024 | 7 | a https://doi.org/10.1158/0008-5472.CAN-16-31722 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Donia, Marcou Copenhagen University Hospital,University of Copenhagen4 aut |
245 | 1 0 | a Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNγ signaling |
264 | 1 | c 2017 |
300 | a 5 s. | |
520 | a Cancer immunotherapy can result in durable tumor regressions in some patients. However, patients who initially respond often experience tumor progression. Here, we report mechanistic evidence of tumoral immune escape in an exemplary clinical case: a patient with metastatic melanoma who developed disease recurrence following an initial, unequivocal radiologic complete regression after T-cell–based immunotherapy. Functional cytotoxic T-cell responses, including responses to one mutant neoantigen, were amplified effectively with therapy and generated durable immunologic memory. However, these immune responses, including apparently effective surveillance of the tumor mutanome, did not prevent recurrence. Alterations of the MHC class I antigen-processing and presentation machinery (APM) in resistant cancer cells, but not antigen loss or impaired IFNγ signaling, led to impaired recognition by tumor-specific CD8þ T cells. Our results suggest that future immunotherapy combinations should take into account targeting cancer cells with intact and impaired MHC class I–related APM. Loss of target antigens or impaired IFNγ signaling does not appear to be mandatory for tumor relapse after a complete radiologic regression. Personalized studies to uncover mechanisms leading to disease recurrence within each individual patient are warranted. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Harbst, Katjau Lund University,Lunds universitet,Lunds Melanomstudiegrupp,Forskargrupper vid Lunds universitet,Melanoma Genomics,Lund Melanoma Study Group,Lund University Research Groups4 aut0 (Swepub:lu)med-kbn |
700 | 1 | a van Buuren, Marit Mu Netherlands Cancer Institute,Neon Therapeutics4 aut |
700 | 1 | a Kvistborg, Piau Netherlands Cancer Institute4 aut |
700 | 1 | a Lindberg, Mattias F.u University of Gothenburg4 aut |
700 | 1 | a Andersen, Rikke Dorotheau Copenhagen University Hospital4 aut |
700 | 1 | a Idorn, Manjau Copenhagen University Hospital4 aut |
700 | 1 | a Ahmad, Shamaila Muniru Copenhagen University Hospital4 aut |
700 | 1 | a Ellebæk, Evau Copenhagen University Hospital4 aut |
700 | 1 | a Mueller, Anjau Martin-Luther-Universität Halle-Wittenberg4 aut |
700 | 1 | a Fagone, Paolou University of Catania4 aut |
700 | 1 | a Nicoletti, Ferdinandou University of Catania4 aut |
700 | 1 | a Libra, Massimou University of Catania4 aut |
700 | 1 | a Lauss, Martinu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Melanoma Genomics,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups4 aut0 (Swepub:lu)med-mlu |
700 | 1 | a Hadrup, Sine Rekeru Copenhagen University Hospital,Technical University of Denmark4 aut |
700 | 1 | a Schmidt, Henriku Aarhus University Hospital4 aut |
700 | 1 | a Andersen, Mads Haldu Copenhagen University Hospital4 aut |
700 | 1 | a Thor Straten, Peru Copenhagen University Hospital4 aut |
700 | 1 | a Nilsson, Jonasu Netherlands Cancer Institute4 aut |
700 | 1 | a Schumacher, Ton Nu University of Gothenburg4 aut |
700 | 1 | a Seliger, Barbarau Martin-Luther-Universität Halle-Wittenberg4 aut |
700 | 1 | a Jönsson, Göranu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-gjo |
700 | 1 | a Svane, Inge Marieu Copenhagen University Hospital4 aut |
710 | 2 | a Copenhagen University Hospitalb University of Copenhagen4 org |
773 | 0 | t Cancer Researchg 77:17, s. 4562-4566q 77:17<4562-4566x 0008-5472 |
856 | 4 | u http://dx.doi.org/10.1158/0008-5472.CAN-16-3172y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/95d483b6-e0e8-401a-a0d0-bf17b6061b15 |
856 | 4 8 | u https://doi.org/10.1158/0008-5472.CAN-16-3172 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view